Core Viewpoint - Tianyi Medical, a leading manufacturer of blood purification consumables in China, is expected to achieve rapid performance growth driven by the increasing number of ESRD patients, policy benefits, and expansion into overseas markets [1] Group 1: Company Strategy - The company has strategically acquired to complete the CRRT (Continuous Renal Replacement Therapy) full industry chain product matrix, establishing a complete ecological closed loop of "equipment + consumables + services" [1] - Tianyi Medical has formed three main business pillars: blood dialysis consumables, CRRT, and ward care, supported by a clear strategic layout [1] Group 2: Market Potential - The number of ESRD patients is continuously increasing, and the improvement in treatment rates is driving the long-term stable expansion of the blood dialysis market, which is expected to reach 51.515 billion yuan by 2030 [1] - The company is enhancing its competitive advantage through a combination of "internal growth + external expansion" strategies [1]